Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. (Q39076847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

1 reference

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

17

Kazuaki Chayama

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

6

Michio Imamura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

5

Masataka Tsuge

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

7

Shoichi Takahashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

10

Hidenori Ochi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

3

Nobuhiko Hiraga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

16

Hiromitsu Kumada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

15

Fumitaka Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Hiromi Yatsuji

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Chiemi Noguchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Nami Mori

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Eiji Iwao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Yoshifumi Fujimoto

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Hiromi Abe

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Chise Tateno

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Katsutoshi Yoshizato

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

18 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

Antimicrobial Agents and Chemotherapy

30 December 2019

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

3867-3874

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

Near completely humanized liver in mice shows human-type metabolic responses to drugs

30 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Hepatitis B virus infection--natural history and clinical consequences

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Clinical aspects of hepatitis B virus infection

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Acute leukaemia in chronic hepatitis B patients with lamivudine therapy

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1635170

Hepatitis B virus and hepatocellular carcinoma

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16982790

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16982790

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00239-06

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16982790%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference